A. Gutiérrez-Fernández

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

CD19-CAR-T cells are a major therapy for relapsed/refractory B-cell malignancies, yet ~50% of patients relapse after infusion. Clinical data suggest that tisa-cel treatment is associated with higher rates of CD19 mutation than axi-cel, though direct comparisons have been lacking. Although both products target the FMC63...